AN1901: Identification Of GLP-1 Analog Oligomeric States Using SEC-MALS Glucagon-like peptide-1 analogs (GLP-1a), such as liraglutide and semaglutide, represent one of the fastest-growing classes of therapies, with seven FDA-approved treatments and over 50 currently in clinical trials as of 2024
Limitations are also evident in rodent models of neurodegenerative diseases, particularly those induced by toxins such as rotenone or MPTP to mimic Parkinsons disease
Its anti-inflammatory action can also improve scalp health
Research shows that CML cells with the BCR-ABL-T315I mutation treated with AKI603 display features typical of senescent cells, such as increased SA--Gal activity, altered morphology, elevated levels of p53, p21, p27, and p16, as well as SASP secretion [79]